These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26493768)

  • 21. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.
    Pastori D; Lip GYH; Farcomeni A; Del Sole F; Sciacqua A; Perticone F; Marcucci R; Grifoni E; Pignatelli P; Violi F;
    Int J Cardiol; 2018 Aug; 264():58-63. PubMed ID: 29776574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Casamira N; García-Camarero T; Montoro-Ronsano JB; Veiga G; Del Blanco BG; De La Torre JM; Gordon B; García-Dorado D; Sambola A
    Am J Med Sci; 2019 Aug; 358(2):95-103. PubMed ID: 31176420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis.
    Lee SJ; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B
    Int J Cardiol; 2015 Feb; 180():185-91. PubMed ID: 25463361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis From Phase 3 of the GLORIA-AF Registry.
    Bergler-Klein J; Gotcheva N; Kalējs O; Kalarus Z; Kovačić D; Peršić V; Shlyakhto E; Uuetoa T; Huisman MV; Lip GYH; Vinereanu D;
    Am J Ther; 2024 Jan-Feb 01; 31(1):e1-e12. PubMed ID: 38231576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database.
    Giner-Soriano M; Roso-Llorach A; Vedia Urgell C; Castells X; Capellà D; Ferreira-González I; Elorza-Ricart JM; Casajuana M; Troncoso Mariño A; Diògene E; Bolíbar B; Violan C; Morros R
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):97-107. PubMed ID: 27868275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy.
    van Rein N; Heide-Jørgensen U; Lijfering WM; Dekkers OM; Sørensen HT; Cannegieter SC
    Circulation; 2019 Feb; 139(6):775-786. PubMed ID: 30586754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
    Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
    BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Vitamin K and Non-Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients.
    Iftimi AA; Rodríguez-Bernal CL; Peiró S; Bonanad S; Ferrero-Gregori A; Hurtado I; García-Sempere A; Sanfélix-Gimeno G
    Clin Pharmacol Ther; 2022 Jan; 111(1):200-208. PubMed ID: 34242404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.
    Patti G; Pecen L; Lucerna M; Huber K; Rohla M; Renda G; Siller-Matula J; Ricci F; Kirchhof P; De Caterina R
    Am J Med; 2019 Jun; 132(6):749-757.e5. PubMed ID: 30664837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study.
    Staerk L; Fosbøl EL; Lamberts M; Bonde AN; Gadsbøll K; Sindet-Pedersen C; Holm EA; Gerds TA; Ozenne B; Lip GYH; Torp-Pedersen C; Gislason GH; Olesen JB
    Eur Heart J; 2018 May; 39(19):1698-1705a. PubMed ID: 29165556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation After Percutaneous Coronary Intervention.
    Gao X; Ge Z; Kong X; Wang Z; Zuo G; Wang F; Chen S; Zhang J
    Int Heart J; 2019 May; 60(3):546-553. PubMed ID: 31105152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes.
    Gallagher AM; van Staa TP; Murray-Thomas T; Schoof N; Clemens A; Ackermann D; Bartels DB
    BMJ Open; 2014 Jan; 4(1):e003839. PubMed ID: 24468720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
    Gundlund A; Staerk L; Fosbøl EL; Gadsbøll K; Sindet-Pedersen C; Bonde AN; Gislason GH; Olesen JB
    J Intern Med; 2017 Aug; 282(2):164-174. PubMed ID: 28480507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists.
    Carmo J; Moscoso Costa F; Ferreira J; Mendes M
    Thromb Haemost; 2016 Sep; 116(4):754-63. PubMed ID: 27465747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.